You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GD2-Expressing Tumors

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Sarcoma, Osteosarcoma, Neuroblastoma Trial run by the NCI (Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide)

Completed
  • Sarcoma
  • +3 more
  • Anti-GD2-CAR engineered T cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 31, 2023

Diffuse Intrinsic Pontine Glioma, High Grade Glioma, Embryonal Tumor Trial in Houston ((C7R)-GD2.CART cells, Cyclophosphamide,

Recruiting
  • Diffuse Intrinsic Pontine Glioma
  • +3 more
  • (C7R)-GD2.CART cells
  • +2 more
  • Houston, Texas
    Texas Children's Hospital
Feb 7, 2022

Neuroblastoma, Neuroblastoma Recurrent, GD2-positive Solid Tumors Trial in Roma (GD2-CART01)

Recruiting
  • Neuroblastoma
  • +5 more
  • GD2-CART01
  • Roma, Italy
    Ospedale Pediatrico Bambino Gesù
Mar 9, 2022

Brain Tumor, Pediatric, Medulloblastoma, Childhood, Embryonal Tumor Trial (GD2-CART01 (iC9-GD2-CAR T-cells))

Not yet recruiting
  • Brain Tumor, Pediatric
  • +6 more
  • GD2-CART01 (iC9-GD2-CAR T-cells)
  • (no location specified)
Mar 18, 2022

Neuroblastoma Trial in Houston (GINAKIT Cells, Cyclophosphamide, Fludarabine)

Active, not recruiting
  • Neuroblastoma
  • GINAKIT Cells
  • +2 more
  • Houston, Texas
    Texas Children's Hospital
Jan 18, 2023

Lung Cancer, Small Cell Lung Carcinoma, Non Small Cell Lung Cancer Trial in Chapel Hill (iC9.GD2.CAR.IL-15 T Infusion)

Not yet recruiting
  • Lung Cancer
  • +2 more
  • iC9.GD2.CAR.IL-15 T Infusion
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Nov 16, 2022

Anatomic Stage IV Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma Trial in Columbus (procedure, drug, biological)

Not yet recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • HER2-Negative Breast Carcinoma
  • Biospecimen Collection
  • +5 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Aug 30, 2023

SCLC, Malignant Melanoma, Sarcoma Trial (GD2-SADA:177Lu-DOTA Complex)

Not yet recruiting
  • SCLC
  • +2 more
  • GD2-SADA:177Lu-DOTA Complex
  • (no location specified)
May 4, 2022

Her2-positive/Low-expression Urinary and Digestive Tract Tumors Trial in Beijing (BL-M07D1)

Not yet recruiting
  • Her2-positive/Low-expression Urinary and Digestive Tract Tumors
  • Beijing, Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
Sep 8, 2023

Brain and CNS Tumors, Intraocular Melanoma, Lung Cancer Trial in New York (genetic, other, radiation)

Active, not recruiting
  • Brain and Central Nervous System Tumors
  • +9 more
  • DNA analysis
  • +4 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Oct 28, 2021

Neuroblastoma, Osteosarcoma Trial in Chapel Hill (iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine)

Recruiting
  • Neuroblastoma
  • Osteosarcoma
  • iC9.GD2.CAR.IL-15 T-cells
  • +2 more
  • Atlanta, Georgia
  • +1 more
Jan 4, 2023

Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma Trial in Bethesda, Seattle, Madison (Cyclophosphamide,

Recruiting
  • Recurrent Neuroblastoma
  • +3 more
  • Palo Alto, California
  • +3 more
Jan 25, 2023

Advanced Solid Tumor, Advanced Lung Cancer, Advanced Gastric Carcinoma Trial in Beijing, Shanghai (IMM2902)

Recruiting
  • Advanced Solid Tumor
  • +3 more
  • Beijing, China
  • +1 more
Apr 6, 2023

Solid Tumor Trial in Shenzhen (bi-4SCAR GD2/PSMA T cells)

Recruiting
  • Solid Tumor
  • bi-4SCAR GD2/PSMA T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022

Salivary Gland Tumors Trial in Beijing (RC48-ADC)

Recruiting
  • Salivary Gland Tumors
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Oct 28, 2022

HER2+ Advanced Breast Cancer, Other Solid Tumors Trial (ADCC-R-Epo-R T-cells + Trastuzumab, Erythropoietin beta, Fludarabine and

Not yet recruiting
  • HER2+ Advanced Breast Cancer
  • Other Solid Tumors
  • ADCC-R-Epo-R T-cells + Trastuzumab
  • +2 more
  • (no location specified)
Aug 31, 2023

HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification Trial in San Antonio, Fairfax (ORM-5029)

Not yet recruiting
  • HER2-positive Breast Cancer
  • +3 more
  • San Antonio, Texas
  • +1 more
Aug 22, 2022

Solid Tumors Trial (TCR-T cells, Fludarabine, Cyclophosphamide Capsules)

Not yet recruiting
  • Solid Tumors
  • TCR-T cells
  • +4 more
  • (no location specified)
Dec 12, 2022

HER2 Expressing or Mutated Advanced Malignant Solid Tumors Trial in China (GQ1005)

Recruiting
  • HER2 Expressing or Mutated Advanced Malignant Solid Tumors
  • Beijing, Beijing, China
  • +19 more
Nov 23, 2023

Advanced Solid Tumors Trial in Shanghai, Chengdu (SHR-A1811, Fluzoparib Capsule)

Enrolling by invitation
  • Advanced Solid Tumors
  • Shanghai, Shanghai, China
  • +1 more
Jun 28, 2022

Advanced Solid Tumor Trial in Dallas (TCRT-ESO-A2)

Withdrawn
  • Advanced Solid Tumor
  • TCRT-ESO-A2
  • (no location specified)
Aug 31, 2022

HER2-expressing Advanced Solid Tumors Trial (SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor

Not yet recruiting
  • HER2-expressing Advanced Solid Tumors
  • SHR-A1811 combined with Pyrotinib.
  • SHR-A1811 combined with other antitumor therapies
  • (no location specified)
Aug 28, 2023

Advanced Solid Tumor Trial (SHR-4602 for injection)

Not yet recruiting
  • Advanced Solid Tumor
  • SHR-4602 for injection
  • (no location specified)
Apr 6, 2023

Advanced Solid Tumor, Advanced Breast Cancer, Advanced Gastric Cancer Trial in Boston, Dallas, Fairfax (IMM2902)

Recruiting
  • Advanced Solid Tumor
  • +2 more
  • Boston, Massachusetts
  • +2 more
Jul 21, 2022

Advanced Solid Tumor Trial in Beijing (KM257 Bispecific antibody)

Not yet recruiting
  • Advanced Solid Tumor
  • KM257 Bispecific antibody
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Apr 8, 2022